SG11201705727TA - 9h-pyrrolo-dipyridine derivatives - Google Patents
9h-pyrrolo-dipyridine derivativesInfo
- Publication number
- SG11201705727TA SG11201705727TA SG11201705727TA SG11201705727TA SG11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA SG 11201705727T A SG11201705727T A SG 11201705727TA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrrolo
- dipyridine
- derivatives
- dipyridine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153448 | 2015-02-02 | ||
| PCT/EP2016/051993 WO2016124508A1 (en) | 2015-02-02 | 2016-01-29 | 9h-pyrrolo-dipyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201705727TA true SG11201705727TA (en) | 2017-08-30 |
Family
ID=52477553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201705727TA SG11201705727TA (en) | 2015-02-02 | 2016-01-29 | 9h-pyrrolo-dipyridine derivatives |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180022748A1 (en) |
| EP (1) | EP3253762B1 (en) |
| JP (1) | JP6579670B2 (en) |
| KR (1) | KR102621513B1 (en) |
| CN (1) | CN107207508B (en) |
| AU (1) | AU2016214537B2 (en) |
| BR (1) | BR112017016311A2 (en) |
| CA (1) | CA2973648C (en) |
| CL (1) | CL2017001923A1 (en) |
| DK (1) | DK3253762T3 (en) |
| EA (1) | EA036518B1 (en) |
| ES (1) | ES2875734T3 (en) |
| IL (1) | IL253381B (en) |
| MX (1) | MX2017009505A (en) |
| MY (1) | MY191590A (en) |
| SG (1) | SG11201705727TA (en) |
| WO (1) | WO2016124508A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2247558B2 (en) | 2008-02-14 | 2024-07-03 | Eli Lilly and Company | Novel imaging agents for detecting neurological dysfunction |
| MX2017009505A (en) * | 2015-02-02 | 2017-11-02 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives. |
| CN109475648B (en) * | 2016-07-22 | 2023-03-14 | Ac免疫有限公司 | Compounds for imaging TAU protein aggregates |
| WO2018015546A1 (en) | 2016-07-22 | 2018-01-25 | Ac Immune S.A. | Compounds for imaging tau protein aggregates |
| CA3035624A1 (en) * | 2016-09-09 | 2018-03-15 | F. Hoffmann-La Roche Ag | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole |
| WO2018102067A2 (en) * | 2016-11-01 | 2018-06-07 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| RU2019138538A (en) | 2017-06-02 | 2021-07-09 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | AMYLOID β-PROTEIN REDUCER |
| WO2018221728A1 (en) | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | Agent for preventing or treating alzheimer-type dementia |
| RU2759727C2 (en) | 2017-06-02 | 2021-11-17 | ФУДЖИФИЛМ Тояма Кемикал Ко., Лтд. | Drug for prevention or treatment of brain atrophy |
| KR20190138696A (en) | 2017-06-02 | 2019-12-13 | 후지필름 도야마 케미컬 가부시키가이샤 | Prevention or treatment of spinal cord cerebellar degeneration |
| AU2018277982B2 (en) * | 2017-06-02 | 2021-04-08 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating tauopathy |
| JP7227914B2 (en) | 2017-10-30 | 2023-02-22 | 富士フイルム富山化学株式会社 | Emopamil-binding protein binding agent and its use |
| WO2019145292A1 (en) * | 2018-01-24 | 2019-08-01 | Ac Immune Sa | Azacarboline compounds for the detection of tau aggregates |
| US20210038747A1 (en) * | 2018-01-24 | 2021-02-11 | Ac Immune Sa | Novel method of preparing an imaging compound |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| JP2022540935A (en) | 2019-07-17 | 2022-09-20 | アルビナス・オペレーションズ・インコーポレイテッド | TAU PROTEIN TARGETING COMPOUNDS AND RELATED METHODS OF USE |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268771A (en) | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | Azacarbazoles |
| WO2008132454A1 (en) * | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| EP2247558B2 (en) * | 2008-02-14 | 2024-07-03 | Eli Lilly and Company | Novel imaging agents for detecting neurological dysfunction |
| JP5557849B2 (en) * | 2008-12-19 | 2014-07-23 | ブリストル−マイヤーズ スクイブ カンパニー | Carbazole and carboline kinase inhibitors |
| WO2013176698A1 (en) | 2012-05-22 | 2013-11-28 | Eli Lilly And Company | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
| WO2014194169A1 (en) | 2013-05-31 | 2014-12-04 | The General Hospital Corporation | Radiosynthesis of tau radiopharmaceuticals |
| CN105379130B (en) * | 2013-07-24 | 2017-08-22 | 瑞典爱立信有限公司 | The relevant method and apparatus of reception with radio signal |
| AR097931A1 (en) * | 2013-10-08 | 2016-04-20 | Hoffmann La Roche | DERIVATIVES OF DIAZACARBAZOL AS TAU LIGANDS FOR PET |
| WO2015110263A1 (en) * | 2014-01-21 | 2015-07-30 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins |
| MX2017009505A (en) * | 2015-02-02 | 2017-11-02 | Ucb Biopharma Sprl | 9h-pyrrolo-dipyridine derivatives. |
-
2016
- 2016-01-29 MX MX2017009505A patent/MX2017009505A/en unknown
- 2016-01-29 DK DK16702121.1T patent/DK3253762T3/en active
- 2016-01-29 US US15/547,980 patent/US20180022748A1/en not_active Abandoned
- 2016-01-29 AU AU2016214537A patent/AU2016214537B2/en active Active
- 2016-01-29 ES ES16702121T patent/ES2875734T3/en active Active
- 2016-01-29 SG SG11201705727TA patent/SG11201705727TA/en unknown
- 2016-01-29 KR KR1020177024371A patent/KR102621513B1/en active IP Right Grant
- 2016-01-29 EA EA201791733A patent/EA036518B1/en not_active IP Right Cessation
- 2016-01-29 MY MYPI2017702668A patent/MY191590A/en unknown
- 2016-01-29 JP JP2017540724A patent/JP6579670B2/en active Active
- 2016-01-29 CN CN201680008314.3A patent/CN107207508B/en active Active
- 2016-01-29 CA CA2973648A patent/CA2973648C/en active Active
- 2016-01-29 WO PCT/EP2016/051993 patent/WO2016124508A1/en active Application Filing
- 2016-01-29 BR BR112017016311A patent/BR112017016311A2/en not_active Application Discontinuation
- 2016-01-29 EP EP16702121.1A patent/EP3253762B1/en active Active
-
2017
- 2017-07-10 IL IL253381A patent/IL253381B/en active IP Right Grant
- 2017-07-27 CL CL2017001923A patent/CL2017001923A1/en unknown
-
2020
- 2020-01-22 US US16/749,537 patent/US11312716B2/en active Active
-
2022
- 2022-03-21 US US17/700,075 patent/US12006316B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2875734T3 (en) | 2021-11-11 |
| US11312716B2 (en) | 2022-04-26 |
| IL253381B (en) | 2020-10-29 |
| US12006316B2 (en) | 2024-06-11 |
| CA2973648C (en) | 2023-09-26 |
| EP3253762A1 (en) | 2017-12-13 |
| US20220213103A1 (en) | 2022-07-07 |
| WO2016124508A1 (en) | 2016-08-11 |
| CN107207508A (en) | 2017-09-26 |
| EA036518B1 (en) | 2020-11-18 |
| KR102621513B1 (en) | 2024-01-04 |
| JP2018503673A (en) | 2018-02-08 |
| EP3253762B1 (en) | 2021-05-05 |
| CN107207508B (en) | 2020-02-28 |
| EA201791733A1 (en) | 2018-01-31 |
| AU2016214537A1 (en) | 2017-08-03 |
| CL2017001923A1 (en) | 2018-02-16 |
| AU2016214537B2 (en) | 2018-05-10 |
| JP6579670B2 (en) | 2019-09-25 |
| CA2973648A1 (en) | 2016-08-11 |
| US20180022748A1 (en) | 2018-01-25 |
| MY191590A (en) | 2022-06-30 |
| KR20170113607A (en) | 2017-10-12 |
| BR112017016311A2 (en) | 2018-03-27 |
| MX2017009505A (en) | 2017-11-02 |
| IL253381A0 (en) | 2017-09-28 |
| DK3253762T3 (en) | 2021-07-19 |
| US20210047326A1 (en) | 2021-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1255045A1 (en) | Substituted oxopyridine derivatives | |
| IL253311A0 (en) | גידול ירוק תוך מבני | |
| IL253381A0 (en) | 9h-pyrrolo-dipyridine derivatives | |
| HK1245258A1 (en) | New difluoroketamide derivatives | |
| SG11201609205WA (en) | Heterocyclyl-butanamide derivatives | |
| DK3380145T3 (en) | Injektionsapparat | |
| PT3131898T (en) | Fluoroalkylfluorene derivatives | |
| DK3272750T3 (en) | Morphinan-derivat | |
| PL3418273T3 (en) | Flavagline derivatives | |
| IL248773A0 (en) | Naphthyridinedione derivatives | |
| IL248629B (en) | Cycloalkyl-linked diheterocycle derivatives | |
| IL251005B (en) | Pyrido-oxazinone derivatives | |
| PL3119744T3 (en) | 2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives | |
| HK1259107A1 (en) | Aminoazole derivative | |
| DK3242882T3 (en) | Cgrp-antagonistpeptider | |
| PT3319956T (en) | Substituted oxopyridine derivatives | |
| GB201510814D0 (en) | Van2Campervan | |
| GB201509898D0 (en) | Lookma | |
| GB201509056D0 (en) | Liqui-glove | |
| GB201507213D0 (en) | Immagine | |
| GB201505689D0 (en) | iHandbag | |
| GB201504463D0 (en) | Fabricks | |
| GB201502787D0 (en) | Macheete | |
| GB201501829D0 (en) | Drydam |